Abstract：Objective：To study the clinical efficacy of Yiqi Lifei Prescription in the adjuvant treatment of bronchial asthma and its effect on inflammatory factors and lung function. Methods：A total of 100 cases of patients with bronchial asthma admitted to the Respiratory Department of Huzhou Central Hospital from January 2020 to December 2022 were selected and divided into the observation group and the control group according to the random number table method， with 50 cases in each group. Both groups were given routine treatment for bronchial asthma；the control group was additionally treated with Montelukast Sodium on the basis of conventional treatment， and the observation group was additionally treated with Montelukast Sodium combined with Yiqi Lifei Prescription on the basis of conventional treatment. Both groups were treated for one month. Observed the clinical effects in the two groups，and compared the lung function and levels of inflammatory factors， T lymphocyte immune function and traditional Chinese medicine syndrome scores between the two groups before and after treatment. Results：After treatment， the total effective rate of clinical effect was 94.00% in the observation group and 68.00% in the control group， the difference between the two groups being significant (P＜0.05). After treatment， forced expiratory volume in the first second (FEV1)，forced vital capacity (FVC) and peak expiratory flow (PEF) in the two groups were increased when compared with those before treatment， and the above indexes in the observation group were higher than those in the control group，differences being significant (P＜0.05). After treatment，the levels of interleukin-6 (IL-6)，interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α) in the two groups were decreased when compared with those before treatment， and the levels in the observation group were lower than those in the control group，differences being significant (P＜0.05). After treatment， the levels of T lymphocyte CD3+ and CD4+ were elevated in the two groups when compared with those before treatment，and the levels in the observation group were higher than those in the control group，differences being significant (P＜0.05)；T lymphocyte CD8+ levels were reduced in the two groups when compared with those before treatment，and the level in the observation group was lower than that in the control group， with significant differences (P＜0.05). After treatment， traditional Chinese medicine syndrome scores in the two groups were decreased， and the score in the observation group was lower than that in the control group，differences being significant (P＜0.05). Conclusion：Yiqi Lifei Prescription in the adjuvant treatment of bronchial asthma can effectively reduce the levels of inflammatory factors， improve cellular immune function and enhance lung function.